Concepedia

Publication | Open Access

<i>DNMT3A</i> Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia

DOIFull Paper Access

53

Citations

26

References

2015

Year

Alison R. Sehgal, Phyllis A. Gimotty, Jianhua Zhao, Jingmei Hsu, Robert Daber, Jennifer D. Morrissette, Selina M. Luger, Alison W. Loren, Martin Carroll
Clinical Cancer Research

Abstract

Patients with DNMT3A-mutated AML have an inferior survival when treated with standard-dose anthracycline induction therapy. This group should be considered for high-dose induction therapy.

References

YearCitations

Page 1